PhD Position within MSCA Doctoral Network MMM, Tübingen, Germany

February 5th, 2026|

The position is available at the research division „Translational Genomics of Neurodegenerative Diseases“ of Prof. Synofzik, located at The Hertie Institute for Clinical Brain Research (HIH), University of Tuebingen.   You will be integrated in several translational projects to develop and validate patientspecific, individualized antisense oligonucleotides ...

PhD Position in preclinical development of individualized antisense oligonucleotides (ASOs) for rare neurological diseases at the Hertie Institute for Clinical Brain Research

February 4th, 2026|

About us The research division „Translational Genomics of Neurodegenerative Diseases“ of Prof. Synofzik focuses on genomics, pathophysiology and translational biomarker research as well as treatment development in the field of neurodegenerative diseases, with a special focus on genetic ataxias, motor neuron diseases, and dementias. Prof. ...

Antibody-Oligonucleotide Conjugate (AOC), Scientist/Senior Scientist

November 21st, 2025|

About the Job Title: Antibody-Oligonucleotide Conjugate (AOC), Scientist/Senior Scientist Type: Full-time, On site Location: Boston MA   NuCyRNA Therapeutics NuCyRNA Therapeutics was founded by a small team of scientists with a shared mission: to rethink RNA-targeting therapeutics and bring true disease-modifying treatments to patients with ...

Senior Research Scientist at AstraZeneca – Synthetic chemistry in Oligonucleotide field

October 16th, 2025|

Are you a passionate Scientist with expertise in synthetic chemistry and have a great interest in the development of Oligonucleotide Therapeutics? Do you wish to join a growing team where you will have the opportunity to further exploit our drug discovery platforms? If yes, we ...

Principal Research Scientist, Targeted Drug Delivery

September 22nd, 2025|

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, pain, sickle cell disease and transfusion-dependent ...

Group Leader, Analytical Development – RNA Medicines

July 24th, 2025|

Position Overview We seek a highly innovative and results-driven scientific leader with deep expertise spanning multiple RNA modalities to establish the analytical development group. This role is instrumental in establishing and executing phase-appropriate analytical strategies for raw materials (e.g., novel lipids, targeting ligands, pDNA), drug ...

Go to Top